The product’s efficacy has been confirmed in a full-scale clinical trial in Russia involving 460 COVID patients. In June 2020, with the support of the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), ChemRar Group specialists developed and were the first in the world to release Avifavir® (INN: favipiravir), a direct antiviral for COVID-19 treatment, to the Russian and international markets. Most of the mutations are found in the spike protein structure, in particular in two of its key parts that are recognized by the human immune system.Ī meta analysis of 23 COVID-19 treatment studies for favipiravir is demonstrating a 47% improvement when favipiravir is used in early treatment of coronavirus. The problem of rapid mutation is particularly typical of RNA viruses, such as SARS-CoV-2 (coronavirus). This provides Avifavir® with a major advantage not only over highly specific biologics but also over many other similar nucleoside products prone to inducing rapid evolution of resistant clinical variants. In addition, the virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed in clinical trials. Moscow, DecemChemRar Group announces the Russian Avifavir® (INN: favipiravir) drug is effective against various variants of SARS-CoV-2 (coronavirus), including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp) via three complementary mechanisms, resulting in complete blockade of the viral infection. This provides Avifavir® with a major advantage not only over highly specific biologics but also over many other similar nucleoside products. The virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed in clinical trials.
ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and OmicronĪvifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp).
0 kommentar(er)
